R
RHYTHM PHARMACEUTICALS INC
NASDAQ: RYTM (Rhythm Pharmaceuticals, Inc.)
最近更新时间: 2小时之前96.06
-2.48 (-2.52%)
前收盘价格 | 98.54 |
收盘价格 | 98.77 |
成交量 | 1,066,930 |
平均成交量 (3个月) | 726,325 |
市值 | 6,380,314,112 |
价格/销量 (P/S) | 38.34 |
股市价格/股市净资产 (P/B) | 84.89 |
52周波幅 | |
利润日期 | 4 Nov 2025 |
营业毛利率 | -123.28% |
营业利益率 (TTM) | -143.73% |
稀释每股收益 (EPS TTM) | -2.80 |
季度收入增长率 (YOY) | 25.90% |
总债务/股东权益 (D/E MRQ) | 69.65% |
流动比率 (MRQ) | 3.30 |
营业现金流 (OCF TTM) | -113.49 M |
杠杆自由现金流 (LFCF TTM) | -96.71 M |
资产报酬率 (ROA TTM) | -51.33% |
股东权益报酬率 (ROE TTM) | -150.20% |
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 混合的 | 看跌 |
Biotechnology (全球的) | 混合的 | 看跌 | |
股票 | Rhythm Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.0
分析师共识 | 1.5 |
内部交易活动 | NA |
价格波动 | -0.5 |
技术平均移动指标 | 3.5 |
技术振荡指标 | -0.5 |
平均 | 1.00 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |
|
部门 | Healthcare |
行业 | Biotechnology |
投资方式 | Small Growth |
内部持股比例 | 0.65% |
机构持股比例 | 103.78% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Baker Bros. Advisors Lp | 30 Jun 2025 | 5,604,483 |
Ra Capital Management, L.P. | 30 Jun 2025 | 5,561,359 |
Primecap Management Co/Ca/ | 30 Jun 2025 | 4,878,037 |
Nea Management Company, Llc | 30 Jun 2025 | 2,909,956 |
Perceptive Advisors Llc | 30 Jun 2025 | 2,418,299 |
Federated Hermes, Inc. | 30 Jun 2025 | 1,686,494 |
Westfield Capital Management Co Lp | 30 Jun 2025 | 1,629,468 |
52周波幅 | ||
目标价格波幅 | ||
高 | 135.00 (JMP Securities, 40.54%) | 购买 |
中 | 107.00 (11.39%) | |
低 | 95.00 (B of A Securities, -1.10%) | 购买 |
95.00 (Needham, -1.10%) | 购买 | |
平均值 | 110.00 (14.51%) | |
总计 | 10 购买 | |
平均价格@调整类型 | 89.69 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
HC Wainwright & Co. | 07 Aug 2025 | 100.00 (4.10%) | 购买 | 92.48 |
Guggenheim | 06 Aug 2025 | 120.00 (24.92%) | 购买 | 90.01 |
JMP Securities | 06 Aug 2025 | 135.00 (40.54%) | 购买 | 90.01 |
26 Jun 2025 | 84.00 (-12.55%) | 购买 | 61.45 | |
Morgan Stanley | 06 Aug 2025 | 109.00 (13.47%) | 购买 | 90.01 |
Canaccord Genuity | 18 Jul 2025 | 105.00 (9.31%) | 购买 | 89.20 |
B of A Securities | 10 Jul 2025 | 95.00 (-1.10%) | 购买 | 89.04 |
Leerink Partners | 10 Jul 2025 | 102.00 (6.18%) | 购买 | 89.04 |
07 Jul 2025 | 88.00 (-8.39%) | 购买 | 66.39 | |
Oppenheimer | 10 Jul 2025 | 110.00 (14.51%) | 购买 | 89.04 |
Wells Fargo | 10 Jul 2025 | 129.00 (34.29%) | 购买 | 89.04 |
Needham | 09 Jul 2025 | 95.00 (-1.10%) | 购买 | 89.00 |
显示更多 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合